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Abstract: Fixed combinations of medications that lower intraocular pressure (IOP) are 
increasingly used in the treatment of glaucoma and ocular hypertension and offer several 
potential advantages over combined use of the separate component medications including 
enhanced convenience, improved adherence, reduced exposure to preservatives, and possible 
cost savings. This review aims to examine the current role of IOP-lowering fixed combinations in 
disease management. The results of studies that compared the efficacy and safety of IOP-lowering 
fixed combinations with their component medications are summarized, including those fixed 
combinations that consist of a prostaglandin analog and timolol. The fixed combinations currently 
available for use in the United States are fixed-combination dorzolamide/timolol (FCDT) and 
fixed-combination brimonidine/timolol (FCBT). Both of these fixed combinations reduce IOP 
more effectively than their component medications used separately as monotherapy. FCBT 
therapy also demonstrates a more favorable safety profile and reduced ocular allergy compared 
to monotherapy with brimonidine, a component medication. Few studies have directly compared 
the efficacy and safety of FCDT and FCBT, but available evidence suggests that FCBT is at least 
as effective as FCDT in lowering IOP and is more comfortable and better tolerated. Additional 
studies are needed to further evaluate the comparative efficacy and tolerability of FCDT and 
FCBT in the management of glaucoma and ocular hypertension.
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The goal of treatment in glaucoma and ocular hypertension is to reduce intraocular 
pressure (IOP) to a target pressure sufficiently low to prevent glaucomatous progression. 
The most commonly used classes of IOP-lowering medications are the prostaglandin 
analogs, beta-adrenergic receptor antagonists (beta-blockers), alpha adrenergic receptor 
agonists (alpha agonists), and carbonic anhydrase inhibitors (CAIs). For many patients, 
a single medication is insufficient to reduce IOP to the target pressure, and the treatment 
regimen includes 2, 3, or more medications from different classes.
In recent years the number and use of fixed combinations of IOP-lowering medications 
for treatment in glaucoma and ocular hypertension has grown substantially. These fixed 
combinations contain 2 medications in a single bottle and offer several advantages 
over concomitant use of the medications from separate bottles. Most important is the 
increase in patient convenience that results from the use of fewer bottles and eyedrops of 
medication and sometimes from dosing fewer times each day. The improved convenience 
of a regimen containing a fixed combination rather than 2 separate medications is 
likely to lead to better adherence. Although few, if any, studies have directly evaluated Clinical Ophthalmology 2010:4 
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adherence to IOP-lowering fixed combinations compared with 
the component medications used separately, there is evidence 
that adherence in glaucoma is better when regimens are simple 
rather than complex.1 A retrospective study using prescription 
data from a large national healthcare provider concluded that 
the rate of prescription refills was reduced when patients 
added a second prescription to their IOP-lowering regimen.2 
In other disease states, studies have shown significantly 
better adherence with fixed combinations (1 pill) than 
with the separate components (2 pills). For example, in 
systemic hypertension, another chronic asymptomatic 
disease associated with low levels of long-term adherence 
to therapy,3 retrospective studies using pharmacy records 
showed that patients were more apt to refill a prescription 
for a fixed combination than 2 separate prescriptions for the 
component medications,4 and patients on a fixed combination 
had medication available for more days of therapy compared 
with patients on the separate component drugs.5
Because there is no possibility of a washout effect and no 
need to wait between instillation of the separate individual 
medications, both efficacy and adherence may be enhanced 
when a fixed combination is used rather than the separate 
component medications. Use of a fixed combination may also 
represent a safety improvement, because the patient’s overall 
daily exposure to preservative may be decreased. Finally, 
there are potential cost savings associated with the use of 
fixed combinations, especially for patients with prescription 
insurance who have 1 copay for a fixed combination rather 
than 2 for separate medications. Moreover, in the United 
States, the availability of a generic fixed combination of 
dorzolamide and timolol increases access for those patients 
who previously could not afford this therapeutic option.
A disadvantage that should be highlighted is that it is not 
possible to change the drug concentration or dosing schedule 
for one component medication independently of the other 
when using a fixed combination. However, if adherence is 
improved by simplifying the regimen, the advantages of 
using a fixed combination outweigh this disadvantage.
Historical overview of IOP-lowering 
fixed combinations
Fixed combinations containing pilocarpine and another 
IOP-lowering medication have been used historically in 
the treatment of glaucoma. In the United States, however, 
epinephrine/pilocarpine (E-pilo®; Ciba Vision) is not 
currently commercially available, timolol/pilocarpine 
(Timpilo®; Merck & Co., Inc.) never received United 
States Food and Drug Administration (FDA) approval, and 
betaxolol/pilocarpine (Betoptic Pilo®; Alcon Laboratories, Inc.) 
was approved in 1997 but was never marketed. The primary 
reason that pilocarpine combinations are no longer commonly 
used is that the component drugs are not generally preferred 
therapy. Although newer preparations of pilocarpine have 
bypassed the need for frequent dosing of up to 4 times each 
day, the side-effect profile of pilocarpine (most commonly 
blurred vision and decreased night vision, less often eye 
irritation and headache) still limits its usefulness in glaucoma 
therapy. Epinephrine also often shows poor ocular tolerability. 
The selective beta-blocker betaxolol continues to be available. 
Although useful in selected patients with a history of pulmonary 
disease, this medication is not as effective in IOP lowering as 
nonselective beta-blockers such as timolol.6
The fixed combinations currently available for IOP 
lowering in the United States contain timolol and either 
the CAI dorzolamide or the alpha agonist brimonidine. 
Dorzolamide/timolol (Cosopt®; Merck & Co., Inc.) has been 
available since 1998 for reducing IOP in patients who do not 
respond adequately to beta-blockers alone, and it has become 
widely used and accepted. Brimonidine/timolol (Combigan®; 
Allergan, Inc.) became available more recently in 2007 for 
reducing IOP in patients who require adjunctive or replace-
ment therapy due to inadequately controlled IOP. Fixed com-
binations of a once-daily prostaglandin analog (latanoprost, 
bimatoprost, or travoprost) and timolol are available in many 
countries but are not yet approved for use in the United States. 
Studies related to the fixed combinations latanoprost/timolol, 
bimatoprost/timolol, and travaprost/timolol are included in 
this review because of their use in other countries.
Efficacy and safety of fixed 
combinations compared  
with component medications
The efficacy and safety of fixed combinations relative to their 
active components must be evaluated to obtain regulatory drug 
approval. For drug approval by the FDA, a fixed combination 
must have better efficacy than each of the component medi-
cations used as monotherapy. The fixed combination should 
also be as effective as the component medications given 
concomitantly in a 2-bottle regimen. The efficacy and safety 
findings from comparison studies of fixed combinations and 
their component medications7–13 are summarized in Table 1.
Fixed-combination dorzolamide/timolol 
(Cosopt)
Two separate 3-month, randomized, double-masked studies 
reported by Boyle et al7 and Clineschmidt et al8 compared Clinical Ophthalmology 2010:4 
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fixed-combination dorzolamide 2%/timolol 0.5% (FCDT) to 
monotherapy with the component medications. The Boyle 
study was carried out in 335 patients after washout of previ-
ous medications7 and the Clineschmidt study in 253 patients 
after a 3-week run-in on timolol.8 FCDT and timolol were 
dosed twice daily while dorzolamide was dosed thrice daily. 
The results from both studies demonstrated that FCDT was 
more effective than either timolol or dorzolamide alone in 
reducing IOP at both peak and trough effect. The incidence 
of treatment-related adverse events was higher in the FCDT 
therapy group than in the timolol monotherapy group in the 
Clineschmidt study and similar between groups in the Boyle 
study. In each study, the overall incidence of treatment-related 
adverse events was similar with FCDT and dorzolamide 
monotherapy, and the incidence of the most common side 
effects (ocular burning/stinging and taste perversion) was also 
similar with FCDT and dorzolamide alone.7,8 Interestingly, 
in the Clineschmidt study, the incidence of conjunctivitis 
was significantly lower in the FCDT group than in the 
dorzolamide group (0% vs 6%, P = 0.034).8 It should be 
noted that the concentration of the preservative is the same in 
FCDT and dorzolamide, although exposure to preservative 
was greater with dorzolamide because it was dosed 3-times 
daily (tid) vs twice daily (bid). Thus, the observation that 
conjunctivitis was less frequent with the former drug suggests 
that timolol may limit ocular inflammation or allergy when 
it is administered in a fixed combination.
Other  studies  have  compared  FCDT  with  a 
nonfixed combination of dorzolamide and timolol. In 
a 12-week, randomized, double-masked study reported 
by Hutzelmann et al14 299 patients run-in on timolol for 
2 weeks were randomized to treatment with FCDT bid or 
concomitant dorzolamide bid and timolol bid. Based on 
the average of month 2 and month 3 data, FCDT and the 
nonfixed combination of dorzolamide and timolol were 
equivalent in IOP lowering, with the difference in mean 
IOP lowering between treatment groups 0.1 mmHg 
at both peak and trough effect. There was no significant 
difference between the treatment groups in the overall 
incidence of treatment-related adverse events, but eye pain 
was significantly less common in the FCDT group than 
in the concomitant therapy group (0% vs 4%, P = 0.014), 
and on biomicroscopy corneal superficial punctate keratitis 
was also less common with FCDT than with concomitant 
timolol and dorzolamide (1% vs 7%, P = 0.005). In contrast, 
in a 3-month, randomized, double-masked study reported 
by Strohmaier et al15 that compared FCDT bid with con-
comitant dorzolamide tid and timolol bid in 242 patients, 
FCDT treatment was approximately 1 mmHg less effective 
than concomitant therapy with dorzolamide and timolol in 
reducing IOP. The incidence of adverse events was similar 
between treatment groups, but eyelid pain or discomfort 
was significantly more frequent in the FCDT group than in 
the concomitant therapy group (6% of FCDT patients vs 
1% of concomitant therapy patients, P = 0.036).
Several open-label replacement studies have suggested 
that patients may achieve additional IOP lowering when 
they are switched from dorzolamide and a beta-blocker to 
FCDT.16–19 It should be noted that Phase IV trials such as these 
are subject to bias, because the investigators are not masked 
and the study design may influence the study outcomes. For 
example, in 2 of the studies16,17 patients were allowed to be 
on a selective beta-blocker before switching to FCDT, and 
in all 4 studies, there was a possibility of improved adher-
ence after patients entered the study and switched to FCDT. 
Francis et al19 reported a randomized parallel-group study 
of FCDT and concomitant therapy as well as a study of 
FCDT replacement of concomitant therapy, and although the 
efficacy results favored FCDT in the replacement study, the 
randomized controlled trial demonstrated equivalent efficacy 
of FCDT and concomitant dorzolamide plus timolol therapy. 
Overall, the results of these studies suggest that FCDT and 
concomitant dorzolamide plus timolol therapy have similar 
efficacy in lowering IOP.
Fixed-combination latanoprost/timolol 
(Xalacom)
The first fixed combination of a prostaglandin analog and 
timolol to be developed was fixed-combination latanoprost 
0.005%/timolol 0.5% (FCLT) (Xalacom®; Pfizer, Inc.). To 
date, none of the fixed combinations of a prostaglandin 
analog and timolol have received FDA approval for use in 
the United States.
In a 6-month, randomized, double-masked study reported 
by Higginbotham et al9 of FCLT versus its component 
medications used as monotherapy, 418 patients run-in for 
2 to 4 weeks on timolol bid were switched to FCLT once 
daily (qd) in the morning, latanoprost qd in the evening, or 
timolol bid. After 6 months, the mean change from baseline 
diurnal IOP was only approximately 1 mmHg larger in the 
FCLT group than in the latanoprost group. Similar results 
were obtained in a second study of 436 patients that was 
reported by Pfeiffer,10 which was comparable in design to 
the Higginbotham study except that latanoprost monotherapy 
was dosed in the morning. FCLT reduced diurnal IOP by 
1.2 mmHg more than latanoprost monotherapy and 1.9 mmHg Clinical Ophthalmology 2010:4 
Fixed combinations in glaucoma therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
more than timolol monotherapy. In both studies, FCLT 
lowered IOP substantially more than timolol alone. The dif-
ferences in IOP lowering between FCLT and latanoprost alone 
were also statistically significant, but latanoprost monotherapy 
was nearly as effective as FCLT. More recently, a small, 
randomized, head-to-head study in 28 patients also showed 
only a small difference in efficacy (1 mmHg) between FCLT 
and latanoprost alone.20
No statistical analysis of adverse events was reported in 
these studies. Bulbar conjunctival hyperemia was reported for 
twice as many patients in the latanoprost group (18) as in the 
FCLT group (9) in the Higginbotham study,9 but conjunctival 
hyperemia was reported for twice as many FCLT patients (4) 
as latanoprost patients (2) in the Pfeiffer study.10 Therefore 
side effects do not appear to be reduced with FCLT compared 
with latanoprost monotherapy.
A randomized, double-masked, crossover study in 
195 patients showed that FCLT qd in the morning does not lower 
IOP as effectively as concomitant treatment with latanoprost 
qd in the evening and timolol bid.21 However, a subsequent 
12-week, randomized, double-masked, parallel-group study 
in 517 patients demonstrated that FCLT qd in the evening is 
as effective in lowering IOP as concomitant treatment with 
latanoprost qd in the evening and timolol bid.22
Fixed-combination brimonidine/timolol 
(Combigan)
A study reported by Sherwood et al11 compared fixed-
combination brimonidine 2%/timolol 0.5% (FCBT) with 
its component medications used separately as monotherapy. 
In this 12-month, randomized, double-masked study, 
1159 patients with glaucoma or ocular hypertension were 
washed out of any previous IOP-lowering medication and 
randomized to treatment with FCBT bid, brimonidine 2% 
tid, or timolol 0.5% bid. Throughout 12 months of treat-
ment, twice-daily FCBT was significantly more effective 
than either twice-daily timolol or thrice-daily brimonidine 
in reducing IOP. Mean IOP reductions from baseline were 
significantly greater with FCBT compared with timolol 
at all measurements (P  0.002) and compared with 
brimonidine at all measurements except those at 5 PM, after 
the afternoon dose of brimonidine monotherapy (P  0.001). 
As might be expected due to the addition of a second drug, 
the fixed combination was less well tolerated than timolol 
monotherapy. Interestingly, however, FCBT demonstrated 
an improved safety profile compared with brimonidine 
monotherapy. There was a significantly lower incidence of 
treatment-related adverse events (53.0% vs 62.8%; P = 0.006) 
and discontinuations for adverse events (14.3% vs 30.4%; 
P  0.001) in patients treated with FCBT than in those 
treated with brimonidine alone. The rate of ocular allergy 
(allergic conjunctivitis) was 45% lower with FCBT than with 
brimonidine monotherapy (P = 0.020).
The reasons for the decrease in drug-related allergy in 
patients treated with FCBT compared with brimonidine 
alone are not fully understood. The decrease in allergy 
may have been due in part to decreased ocular exposure 
to brimonidine, since FCBT was dosed twice daily and 
brimonidine was dosed thrice daily as recommended in its 
prescribing information. However, in a study of 102 patients 
prospectively treated with twice-daily FCBT compared with 
a historical control group of 102 patients treated with twice-
daily brimonidine monotherapy, the rate of ocular allergy was 
lower with FCBT than with brimonidine monotherapy even 
when both treatments were dosed twice daily.23
A study reported by Goni24 compared FCBT with a 
nonfixed combination of brimonidine and timolol. In this 
12-week, randomized, double-masked study, 371 patients 
run-in on any monotherapy for at least 3 weeks were switched 
to treatment with FCBT bid or concomitant brimonidine bid 
and timolol bid. Throughout 12 weeks of treatment, FCBT 
and the nonfixed combination of brimonidine and timolol 
were equivalent in IOP lowering. Differences between 
treatment groups were 0.30 mmHg for mean change from 
baseline IOP and 0.35 mmHg for mean IOP, and none 
were statistically significant. For patients who were run-in 
on a beta-blocker, the switch to FCBT provided a mean 
additional IOP reduction of 4.4 to 5.7 mmHg. Both fixed and 
nonfixed brimonidine/timolol treatment were well tolerated, 
and there were no differences in adverse events between 
treatment groups.
Fixed-combination bimatoprost/timolol 
(Ganfort)
The prostaglandin analog bimatoprost has been combined 
with timolol in fixed-combination bimatoprost 0.03%/timolol 
0.5% (FCBimT) (Ganfort®; Allergan, Inc.). In a 3-month, 
randomized, double-masked study reported by Brandt et al12 
of FCBimT versus its component medications used as 
monotherapy, 1061 patients were treated with FCBimT qd 
in the morning, bimatoprost qd in the evening, or timolol 
bid. After 3 months, the mean change from baseline diurnal 
IOP in the FCBimT group (8.1 mmHg) was larger than in 
the timolol group (6.4 mmHg) but not the bimatoprost group 
(7.9 mmHg). Although FCBimT was consistently more 
effective than timolol at reducing IOP, the mean reduction Clinical Ophthalmology 2010:4 
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from baseline IOP was significantly larger with FCBimT than 
with bimatoprost alone at only 5 of 9 follow-up timepoints. 
However, FCBimT demonstrated improved tolerability 
compared with bimatoprost monotherapy. Both the overall 
incidence of treatment-related adverse events and the 
incidence of discontinuations due to adverse events were 
significantly reduced in the FCBimT group compared with 
the bimatoprost group. The most frequent side effect of 
treatment, conjunctival hyperemia, was reported for 22.7% 
of FCBimT patients compared with 38.5% of bimatoprost 
patients.
In a 3-week, randomized, double-masked, parallel-group 
study reported by Hommer et al25 FCBimT was compared 
with nonfixed bimatoprost and timolol or with bimatoprost 
alone in 445 patients. FCBimT qd in the morning reduced 
IOP as effectively as concomitant treatment with bimato-
prost qd in the evening and timolol bid at the 3 follow-up 
timepoints in the study (hours 1, 2, and 8 at week 3).25 On 
biomicroscopy, the incidence of a clinically significant 
increase in conjunctival hyperemia was significantly lower 
with FCBimT (8.5%) than with bimatoprost monotherapy 
(18.9%) and numerically lower than with the nonfixed com-
bination of bimatoprost and timolol (12.5%).
Fixed-combination travoprost/timolol 
(DuoTrav)
The prostaglandin analog travoprost has been combined 
with timolol in fixed-combination travoprost 0.004%/timolol 
0.5% (FCTT) (DuoTrav®; Alcon Laboratories, Inc.). In a 
3-month, randomized, double-masked study reported by 
Barnebey et al13 of FCTT versus its component medications 
used as monotherapy, 263 patients were treated with FCTT 
qd in the morning, travoprost qd in the evening, or timolol 
bid. FCTT reduced IOP substantially more than timolol 
alone throughout the study. At month 3, the mean reduc-
tion from baseline IOP was approximately 1.1 to 2.4 mmHg 
larger in the FCTT group than in the travoprost group, 
but the difference was statistically significant at only 
2 of 3 timepoints, and the reductions were measured from a 
baseline IOP that was approximately 0.6 mmHg higher in the 
FCTT group. No statistical analysis of adverse events in the 
study was reported. The incidence of conjunctival hyperemia 
was 14.1% in the FCTT group, 11.6% in the travoprost group, 
and 1.1% in the timolol group.
Two studies have evaluated the efficacy and safety of 
FCTT qd in the morning compared with concomitant 
treatment with travoprost qd in the evening and timolol qd 
in the morning.26,27 In the study reported by Schuman et al26 
the mean reduction from baseline IOP was greater with 
concomitant therapy than with FCTT by up to approximately 
1.0 mmHg at 5 of 9 follow-up timepoints and statistically 
similar between groups at the remaining timepoints. 
Similarly, in the study reported by Hughes et al27 mean IOPs 
were significantly lower in the concomitant therapy group 
than in the FCTT group by up to approximately 1.0 mmHg 
at 4 of 9 timepoints during treatment. These results suggest 
that FCTT is slightly less effective than concomitant therapy 
with travoprost and timolol. The overall incidence of adverse 
events was similar between treatment groups in both studies, 
although in one study the incidence of conjunctival hyper-
emia was lower with FCTT (14.3%) than with concomitant 
therapy (23.4%).26
Comparison of dorzolamide/timolol 
and brimonidine/timolol
In a 2-month, open-label, surveillance study (CEED II) of 
fixed brimonidine/timolol use in 2133 patients at 123 centers 
in Canada, patients switched from FCDT monotherapy 
to FCBT monotherapy achieved average additional IOP 
lowering of 2.2 to 2.6 mmHg.28 As discussed previously, 
open-label drug replacement studies do not provide strong 
evidence of comparative drug efficacy, but the safety and 
tolerability findings of the study may be more informative. 
On a questionnaire given in the study, patients reported 
less burning, stinging, and metallic taste after switching 
from FCDT to FCBT, suggesting that fixed brimonidine/
timolol may be better tolerated than fixed dorzolamide/
timolol.28
In support of this suggestion, in a randomized, double-
masked, paired-eye study in 30 normal subjects, subject 
scores of ocular discomfort at 30 to 40 seconds after 
eyedrop instillation were significantly lower with fixed 
brimonidine/timolol than with fixed dorzolamide/timolol 
(P  0.001).29 Although it is possible that the threshold for 
tolerating side effects is lower in normal subjects than in 
glaucoma patients with a potentially blinding eye disease, 
these results suggest that FCBT eyedrops are more comfort-
able than FCDT eyedrops upon instillation.29 The difference 
between the fixed combinations in ocular comfort may result 
from the difference in the pH of the formulations. Burning 
and stinging are commonly associated with use of acidic 
ophthalmic solutions,30,31 and FCDT is formulated at a pH 
of approximately 5.65. In contrast, the pH of FCBT ranges 
from 6.5 to 7.3 during its shelf life. The neutral pH of the 
fixed brimonidine/timolol formulation is likely to account 
for its better tolerability.Clinical Ophthalmology 2010:4 
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The comparative efficacy and tolerability of FCDT and 
FCBT has not been well studied in head-to-head trials. In a 
randomized, investigator-masked, crossover study comparing 
FCDT and FCBT in 30 patients, there were no statistically 
significant differences in efficacy after 4 weeks of treatment.32 
The study was underpowered to detect a 2 mmHg difference 
in efficacy between the fixed combinations.32 Nonetheless, 
the similarity in the mean diurnal IOP reductions provided 
by the fixed combinations (7.4 mmHg for FCDT and 7.8 
mmHg for FCBT) suggest that FCDT and FCBT had similar 
efficacy in reducing IOP. Ocular stinging/burning was sig-
nificantly more common with fixed dorzolamide/timolol 
(9 patients) than with fixed brimonidine/timolol (1 patient, 
P = 0.027). In a randomized parallel-group comparison study, 
after 3 months of treatment the mean IOP was lower (15.6 
vs 17.2 mmHg, P = 0.040) and the mean reduction from 
baseline IOP was greater (7.7 vs 6.7 mmHg, P = 0.040) in 
patients treated with FCBT monotherapy than in patients 
treated with FCDT monotherapy.33 On a comfort/tolerability 
questionnaire, patients treated with fixed brimonidine/timolol 
reported significantly less stinging (P  0.001), burning 
(P = 0.015), and unusual taste (P = 0.005) compared with 
patients treated with fixed dorzolamide/timolol.
Overall, the results of the clinical studies that have 
been published suggest that fixed brimonidine/timolol pro-
vides similar or greater IOP lowering compared with fixed 
dorzolamide/timolol and also demonstrates better ocular 
tolerability upon instillation. The greater comfort of fixed 
brimonidine/timolol eyedrops might lead to better adherence 
to treatment. Moreover, fixed brimonidine/timolol has a better 
safety profile than brimonidine monotherapy. The lower rate 
of ocular allergy associated with fixed brimonidine/timolol 
compared with brimonidine alone is clinically significant, 
because chronic use of brimonidine is sometimes limited 
by the occurrence of ocular allergy. These favorable safety 
and efficacy findings suggest that fixed brimonidine/timolol 
may have an important role in glaucoma management. 
Additional studies are needed to further evaluate the relative 
efficacy and tolerability of fixed brimonidine/timolol and 
fixed dorzolamide/timolol in lowering IOP as well as patient 
adherence and persistence with treatment.
Monotherapy remains the preferred initial choice 
of treatment in glaucoma; these fixed combinations 
should generally be used only when monotherapy has not 
provided low enough IOP. Both fixed dorzolamide/timolol 
and fixed brimonidine/timolol effectively reduce IOP when 
used alone7,8,11 or adjunctively with a prostaglandin analog,28,34 
the most common first-line therapy.35 Further, both fixed 
dorzolamide/timolol7,8 and fixed brimonidine/timolol11 reduce 
IOP more effectively than monotherapy with their component 
medications.
Comment
The use of fixed combinations is preferred over separate 
use of both components primarily to facilitate adherence 
and persistence with treatment. Adherence is an important 
concern in glaucoma because up to 80% of patients may 
not take their medication as prescribed.1 One of the primary 
reasons for nonadherence in glaucoma is the inconvenience 
associated with eyedrop instillation.36 It is more convenient 
(both easier and faster) to instill 1 drop of a fixed combination 
than 2 drops from separate bottles of the component medi-
cations. Moreover, results of a recent study have suggested 
that a substantial proportion of patients on multiple drops 
(22%) wait less than 3 minutes after taking an IOP-lowering 
medication before instilling a second medication.37 For those 
patients, a washout effect may occur, but no washout effect is 
possible when only 1 drop is given rather than 2. Finally, for 
some patients cost is also a significant factor reducing adher-
ence with prescription medications.38 The average wholesale 
price (AWP) of medications changes over time, and based on 
the AWP, the cost of a fixed combination is not necessarily 
less than the cost of buying the components separately.39,40 
However, for patients with prescription insurance and copays, 
the cost of a fixed combination is likely to be less than the 
combined cost of the component medications, reducing one 
possible barrier to compliance with treatment. The availabil-
ity of a generic for FCDT is a potential advantage of use of 
this fixed combination, as it may further reduce the potential 
for cost to be a barrier to compliance.
A fixed combination should contain drugs that are safe 
and effective and that work well in combination with each 
other. The lack of availability of fixed combinations con-
taining pilocarpine in the United States can probably be 
explained by the poor tolerability profile of pilocarpine. In 
contrast, fixed combinations of the prostaglandin analogs 
and timolol have not been approved for use in the United 
States. Based on the studies submitted to the FDA related 
to timolol/latanoprost, it is not clear that the improvement 
in efficacy with the prostaglandin analog/timolol fixed com-
binations relative to prostaglandin analog monotherapy is 
clinically significant. However, given the approval of these 
fixed combinations in other countries, it may be that subsets 
of patients are responsive to this therapy. Furthermore, the 
convenience of having 2 medications in 1 bottle cannot be 
underestimated.Clinical Ophthalmology 2010:4 
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In summary, fixed combinations are important adjuncts 
to the armamentarium of available glaucoma therapies and 
offer critical options for patients who require more than one 
medication to control intraocular pressure.
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